Christoph H. Westphal
Founder chez Longwood Fund Management LLC
Fortune : 18 M $ au 31/03/2024
Profil
Dr. Westphal is co-founder and General Partner of Longwood Fund.
Dr. Westphal earned his M.D.
from Harvard Medical School and Ph.D.
in genetics from Harvard University; and he graduated with a B.A.
summa cum laude and Phi Beta Kappa from Columbia University.
Dr. Westphal has served or currently serves as a member or director of: the Boston Commercial Club, the Biotechnology Industry Organization’s (BIO) Emerging Companies Section Governing Board, the Board of Fellows of Harvard Medical School, and the Board of Trustees of the Boston Symphony Orchestra
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
TSCAN THERAPEUTICS, INC.
5,31% | 31/03/2023 | 2 315 423 ( 5,31% ) | 18 M $ | 31/03/2024 |
Postes actifs de Christoph H. Westphal
| Sociétés | Poste | Début |
|---|---|---|
Longwood Fund Management LLC
 Longwood Fund Management LLC Investment ManagersFinance Longwood Fund Management LLC (Longwood Fund Management) is a venture capital firm founded in 2010 by Christoph H. Westphal, Michelle Dipp and Richard H. Aldrich. The firm is headquartered in Boston, Massachusetts. | Founder | 01/02/2010 |
| Longwood Fund II GP LLC | Corporate Officer/Principal | - |
Longwood Fund LP
 Longwood Fund LP Investment ManagersFinance Longwood Fund LP invests in companies located in the US. The fund targets companies operating in the fields healthcare companies. It provides financing for early stage capital requirements. | Corporate Officer/Principal | 01/01/2010 |
Boston Symphony Orchestra, Inc.
 Boston Symphony Orchestra, Inc. Movies/EntertainmentConsumer Services Boston Symphony Orchestra Inc. performs symphony orchestra concerts. The organization performs concerts in Japan, China, South America, and Europe. The firm offers educational and training programs for professional musicians. The company was founded in 1881 by Henry Lee Higginson and is headquartered in Boston, MA. | Director/Board Member | - |
| Commercial Club of Boston | Corporate Officer/Principal | - |
Recros Medica, Inc.
 Recros Medica, Inc. Medical SpecialtiesHealth Technology Recros Medica, Inc. is a clinical stage medical device company, which engages in the research and development of aesthetic products to enhance appearance. Its product called Nuvellus Focal Contouring System is use by dermatologists, plastic surgeons, and other aesthetic physicians to reduce skin laxity, enhance focal aesthetic contouring, and provide a natural alternative to commercial dermal fillers. The company was founded by Edward Knowlton, David F. Hale, and Cathy L. McCarthy in 2014 and is headquartered in San Diego, CA. | Director/Board Member | 04/01/2018 |
Immunitas Therapeutics, Inc.
 Immunitas Therapeutics, Inc. BiotechnologyHealth Technology Immunitas Therapeutics, Inc. provides cancer therapeutics services. The company was founded by Lea Hachigian, Kai Wucherpfennig, K. Dane Wittrup and Mario Suv? and is headquartered in Cambridge, MA. | Chairman | 18/12/2019 |
ImmuneID, Inc.
 ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | Director/Board Member | - |
Solu Therapeutics
 Solu Therapeutics Pharmaceuticals: MajorHealth Technology Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules. | Director/Board Member | - |
Anciens postes connus de Christoph H. Westphal
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Christoph H. Westphal
| The Trustees of Columbia University in The City of New York | Undergraduate Degree |
| Harvard University | Doctorate Degree |
| Harvard Medical School | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
| VERASTEM, INC. | Health Technology |
| TSCAN THERAPEUTICS, INC. | Health Technology |
| WEREWOLF THERAPEUTICS, INC. | Health Technology |
| PYXIS ONCOLOGY, INC. | Health Technology |
| Entreprise privées | 24 |
|---|---|
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Nanosys, Inc.
 Nanosys, Inc. Chemicals: SpecialtyProcess Industries Nanosys, Inc. develops and manufactures inorganic nanostructures and other related products. It offers Ultra HD television. The company was founded by Paul A. Alivisatos, Stephen Empedocles, Peidong Yang, Robert M. Metcalfe, Jim Heath, Paul McEuen, Christoph H. Westphal, Moungi Bawendi, Lawrence A. Bock, Calvin Y. H. Chow, Chunming Niu, Karen Vergura, Hongkun Park, George Pontis and Charles M. Lieber in 2001 and is headquartered in Milpitas, CA. | Process Industries |
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. | Health Technology |
Sirtris Pharmaceuticals, Inc.
 Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | Health Technology |
PPD Dermatology LLC
 PPD Dermatology LLC Pharmaceuticals: MajorHealth Technology PPD Dermatology LLC develops novel pharmaceutical products and proprietary medical therapies for the dermatology market. The company provides therapies for skin diseases. It was founded in 2006 and is headquartered in Waltham, MA. | Health Technology |
Concert Pharmaceuticals, Inc.
 Concert Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA. | Health Technology |
Alnara Pharmaceuticals, Inc.
 Alnara Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alnara Pharmaceuticals, Inc. develops and commercializes protein therapeutics for the treatment of metabolic diseases. It also develops liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT) for the treatment of exocrine pancreatic insufficiency (EPI). The company was founded by Christoph H. Westphal, Richard H. Aldrich and Alexy L. Margolin in 2008 and is headquartered in Boston, MA. | Health Technology |
Longwood Fund LP
Longwood Fund LP Investment ManagersFinance Longwood Fund LP invests in companies located in the US. The fund targets companies operating in the fields healthcare companies. It provides financing for early stage capital requirements. | Finance |
Flex Pharma, Inc.
 Flex Pharma, Inc. Pharmaceuticals: MajorHealth Technology Flex Pharma, Inc. operates as a clinical-stage biotechnology company. It operates through the Consumer Operations and Drug Development segments. The Consumer Operations segment includes HOTSHOT product and consumer operations. The Drug Development segment engages in the development of innovative and proprietary drug products to treat muscle cramps and spasms associated with severe neurological conditions. The company was founded by Rod MacKinnon, Bruce Bean, Christoph Westphal, Rich Aldrich, Michelle Dipp, and Jennifer M. Cermak in February 2014 and is headquartered in Boston, MA. | Health Technology |
Recros Medica, Inc.
Recros Medica, Inc. Medical SpecialtiesHealth Technology Recros Medica, Inc. is a clinical stage medical device company, which engages in the research and development of aesthetic products to enhance appearance. Its product called Nuvellus Focal Contouring System is use by dermatologists, plastic surgeons, and other aesthetic physicians to reduce skin laxity, enhance focal aesthetic contouring, and provide a natural alternative to commercial dermal fillers. The company was founded by Edward Knowlton, David F. Hale, and Cathy L. McCarthy in 2014 and is headquartered in San Diego, CA. | Health Technology |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Commercial Services |
Polaris Growth Management LLC
 Polaris Growth Management LLC Investment ManagersFinance Polaris Partners is an Independent Venture Capital firm founded in 1996 by Stephen D. Arnold, Jonathan A. Flint and Terrance G. McGuire. Polaris Partners is headquartered in Waltham. | Finance |
GSK Equity Investments Ltd.
 GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Finance |
Exeter Venture Management Company LLC
 Exeter Venture Management Company LLC Investment ManagersFinance Exeter Venture Management Company LLC (Exeter Venture Management Company) is a venture capital subsidiary of International Data Group, Inc. founded in 2002. The firm is headquartered in New York, New York. | Finance |
Hydra Biosciences, Inc.
 Hydra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Hydra Biosciences, Inc. develops pharmaceutical products. It is focused in major therapeutic areas, which include pain, inflammation, renal, anxiety, and pulmonary diseases. The company was founded by Laurie Bartlett Keating, Dean Y. Li, David E. Clapham, and Mark T. Keating in 2001 and is headquartered in Belmont, MA. | Health Technology |
Saegis Pharmaceuticals, Inc.
 Saegis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Saegis Pharmaceuticals, Inc. developed drug therapeutics. Its phase II SGS742 clinical drug treated diseases such as mild cognitive impairment and attention deficit hyperactivity disorder. Its second SGS742 clinical trial provided coronary artery bypass surgery. The company was founded in 1999 and was headquartered in Half Moon Bay, CA. | Health Technology |
Boston Symphony Orchestra, Inc.
Boston Symphony Orchestra, Inc. Movies/EntertainmentConsumer Services Boston Symphony Orchestra Inc. performs symphony orchestra concerts. The organization performs concerts in Japan, China, South America, and Europe. The firm offers educational and training programs for professional musicians. The company was founded in 1881 by Henry Lee Higginson and is headquartered in Boston, MA. | Consumer Services |
Longwood Fund Management LLC
Longwood Fund Management LLC Investment ManagersFinance Longwood Fund Management LLC (Longwood Fund Management) is a venture capital firm founded in 2010 by Christoph H. Westphal, Michelle Dipp and Richard H. Aldrich. The firm is headquartered in Boston, Massachusetts. | Finance |
OvaScience, Inc.
 OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | Health Technology |
| Longwood Fund II GP LLC | |
| Commercial Club of Boston | |
Immunitas Therapeutics, Inc.
Immunitas Therapeutics, Inc. BiotechnologyHealth Technology Immunitas Therapeutics, Inc. provides cancer therapeutics services. The company was founded by Lea Hachigian, Kai Wucherpfennig, K. Dane Wittrup and Mario Suv? and is headquartered in Cambridge, MA. | Health Technology |
ImmuneID, Inc.
ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | Commercial Services |
Solu Therapeutics
Solu Therapeutics Pharmaceuticals: MajorHealth Technology Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules. | Health Technology |
